Latest news with #Enovis
Yahoo
08-07-2025
- Business
- Yahoo
Enovis to Host Second Quarter 2025 Results Conference Call on August 7th
Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901. A replay of the call will also be available on the Enovis website later that day. About Enovis Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit Availability of Information on the Enovis Website Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares at Contact: Kyle RoseVice President, Investor RelationsEnovis Corporationinvestorrelations@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
08-07-2025
- Business
- Globe and Mail
Enovis to Host Second Quarter 2025 Results Conference Call on August 7th
Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at Conference Call/Webcast Information Investors can access the live webcast via a link on the Enovis website. For those planning to participate on the call, please dial (833) 685-0901. A replay of the call will also be available on the Enovis website later that day. About Enovis Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company's extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company's shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit Availability of Information on the Enovis Website Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares at Contact:
Yahoo
29-06-2025
- Business
- Yahoo
5 Insightful Analyst Questions From Enovis's Q1 Earnings Call
Enovis Corporation's first quarter results prompted a negative market reaction, as investors weighed both solid top-line growth and concerns about margin pressures. Management attributed the quarter's revenue gains to strong performance in the Reconstruction (Recon) segment—particularly in U.S. extremities and international markets—along with healthy contributions from Prevention & Recovery (P&R) products. CEO Matthew Trerotola highlighted the impact of recent product launches, noting that the company delivered 'well above market rates in the U.S.' and benefited from expanding its global position. However, ongoing investments in research and supply chain adjustments, as well as the effects of new tariffs, weighed on operating margins. Is now the time to buy ENOV? Find out in our full research report (it's free). Revenue: $558.8 million vs analyst estimates of $558.9 million (8.3% year-on-year growth, in line) Adjusted EPS: $0.81 vs analyst estimates of $0.74 (8.9% beat) Adjusted EBITDA: $99.2 million vs analyst estimates of $98.78 million (17.8% margin, in line) The company lifted its revenue guidance for the full year to $2.24 billion at the midpoint from $2.21 billion, a 1.4% increase Management lowered its full-year Adjusted EPS guidance to $3.03 at the midpoint, a 4.7% decrease EBITDA guidance for the full year is $390 million at the midpoint, below analyst estimates of $409 million Operating Margin: -8.4%, down from -6.8% in the same quarter last year Organic Revenue rose 9.1% year on year (4.8% in the same quarter last year) Market Capitalization: $1.84 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Vik Chopra (Wells Fargo) asked about which tariff mitigation actions would be most durable, with CEO Matthew Trerotola pointing to shifting sourcing out of China as the most sustainable approach. Vijay Kumar (Evercore ISI) questioned if strong gross margin gains were sustainable. CFO Ben Berry responded that favorable business mix and new products were key, with only temporary headwinds expected from tariffs. Robert Marcus (JPMorgan) inquired about free cash flow progression and leverage, with Berry noting seasonality and confirming expectations for improved cash flow and leverage in the 3-3.5x range by year-end. Young Li (Jefferies) sought clarification on why the P&R growth outlook remained conservative despite a strong start. Trerotola explained that the segment faces the greatest tariff impact and diverse end-market risks, warranting a cautious full-year approach. Russell Yuen (William Blair) asked about pricing trends under inflation and tariff scenarios, with Trerotola highlighting a stable pricing environment in P&R but some downward pressure in Recon, partially offset by richer product mix. In the quarters ahead, the StockStory team will be watching (1) the rate and effectiveness of Enovis's tariff mitigation and supply chain diversification, (2) the commercial uptake and surgeon adoption of newly launched Recon and P&R products, and (3) the company's ability to sustain gross margin improvements despite ongoing cost pressures. Execution on integration synergies and cash flow conversion will also be important indicators of operational progress. Enovis currently trades at $32.26, down from $34.14 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it's free). The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-06-2025
- Business
- Yahoo
Jefferies Maintains a Buy on Enovis (ENOV), Sets a $60 PT
Enovis Corporation (NYSE:ENOV) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On May 28, Jefferies analyst Young Li maintained a Buy rating on Enovis Corporation (NYSE:ENOV) and set a price target of $60.00. The positive rating was based on several key factors, as the company reported a strong start to the year with notable growth figures in fiscal Q1 2025. A patient recieving cold therapy treatment using the company's products. Its net sales for the quarter grew 8% on a reported basis compared to the same quarter in 2024, while adjusted EBITDA reached $99 million, or 17.7% of sales. This translates to a 160 basis points growth compared to last year. The analyst attributed the growth to the company's successful commercial execution and integration efforts, as well as additional potential from cross-selling opportunities and new product launches. Enovis Corporation (NYSE:ENOV) is also increasing its free cash flow conversion and expanding margins, which positions it well for future profitability. The analyst further reasoned that the company has an attractive valuation and is trading below its peers, which points toward the potential for multiple expansions. Enovis Corporation (NYSE:ENOV) is a medical technology growth company that develops clinically differentiated solutions to transform workflows and generate better patient outcomes. The company operates through the Prevention & Recovery and Reconstructive segments. While we acknowledge the potential of ENOV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
24-06-2025
- Business
- Yahoo
Entegris, Herc, Enovis, Commercial Vehicle Group, and DexCom Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.4%, S&P 500 +1.0%) on hopes the reported ceasefire between Israel and Iran will hold. This de-escalation in a volatile region helped to ease concerns about potential disruptions to global oil supplies, leading to a notable dip in crude oil prices. Additionally, dovish signals from Federal Reserve Chair Jerome Powell in his Congressional testimony, reaffirming a "wait-and-see" approach on interest rates, further calmed markets, improving investors' appetite for stocks and other risk assets. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Among others, the following stocks were impacted: Semiconductor Manufacturing company Entegris (NASDAQ:ENTG) jumped 7%. Is now the time to buy Entegris? Access our full analysis report here, it's free. Specialty Equipment Distributors company Herc (NYSE:HRI) jumped 7.4%. Is now the time to buy Herc? Access our full analysis report here, it's free. Medical Devices & Supplies - Specialty company Enovis (NYSE:ENOV) jumped 6.2%. Is now the time to buy Enovis? Access our full analysis report here, it's free. Heavy Transportation Equipment company Commercial Vehicle Group (NASDAQ:CVGI) jumped 5.1%. Is now the time to buy Commercial Vehicle Group? Access our full analysis report here, it's free. Patient Monitoring company DexCom (NASDAQ:DXCM) jumped 6.3%. Is now the time to buy DexCom? Access our full analysis report here, it's free. Herc's shares are extremely volatile and have had 34 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 28 days ago when the stock gained 5.1% after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports, shifting the start date to July 9, 2025. Companies with substantial business ties to Europe likely had some relief as the delay reduced near-term cost pressures and preserved cross-border demand. Herc is down 32.1% since the beginning of the year, and at $126.38 per share, it is trading 47.2% below its 52-week high of $239.28 from November 2024. Investors who bought $1,000 worth of Herc's shares 5 years ago would now be looking at an investment worth $4,616. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
